Found: 72
Select item for more details and to access through your institution.
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00905-8
- By:
- Publication type:
- Article
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00888-6
- By:
- Publication type:
- Article
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00883-x
- By:
- Publication type:
- Article
Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease.
- Published in:
- Journal of Neurosurgery, 1989, v. 71, n. 4, p. 481, doi. 10.3171/jns.1989.71.4.0481
- By:
- Publication type:
- Article
Epilepsy Surgery: Historical Highlights 1909–2009.
- Published in:
- Epilepsia (Series 4), 2009, v. 50, p. 131, doi. 10.1111/j.1528-1167.2009.02043.x
- By:
- Publication type:
- Article
The Swamp: The Everglades, Florida, and the Politics of Paradise.
- Published in:
- 2023
- By:
- Publication type:
- Book Review
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
- Published in:
- Current Oncology, 2022, v. 29, n. 3, p. 1575, doi. 10.3390/curroncol29030132
- By:
- Publication type:
- Article
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 93, doi. 10.1111/bjh.18172
- By:
- Publication type:
- Article
Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 532, doi. 10.1111/bjh.17350
- By:
- Publication type:
- Article
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. 552, doi. 10.1002/ajh.26147
- By:
- Publication type:
- Article
Rapid Induction of Messenger RNA for Nitric Oxide Synthase II in Rat Neutrophils In Vivo by Endotoxin and its Suppression by Prednisolone.
- Published in:
- Proceedings of the Society for Experimental Biology & Medicine, 1994, v. 205, n. 3, p. 220, doi. 10.3181/00379727-205-43700
- By:
- Publication type:
- Article
A utopian idea: Cushing, Bailey, Penfield, and the National Institute of Neurological Diseases and Blindness.
- Published in:
- Journal of Neurosurgery, 2023, v. 139, n. 2, p. 579, doi. 10.3171/2022.11.JNS221927
- By:
- Publication type:
- Article
No woman alone: Dorothy Russell's legacy to neurosurgery.
- Published in:
- Journal of Neurosurgery, 2022, v. 136, n. 5, p. 1455, doi. 10.3171/2021.6.jns2150
- By:
- Publication type:
- Article
The birth of experimental neurosurgery: Wilder Penfield at Montreal's Royal Victoria Hospital, 1928-1934.
- Published in:
- Journal of Neurosurgery, 2022, v. 136, n. 2, p. 553, doi. 10.3171/2021.1.JNS203929
- By:
- Publication type:
- Article
Charcot's motor brain map and 19th-century neurosurgery.
- Published in:
- Journal of Neurosurgery, 2021, v. 135, n. 6, p. 1843, doi. 10.3171/2020.10.JNS202651
- By:
- Publication type:
- Article
Penfield, focal microgyria, and epilepsy.
- Published in:
- Journal of Neurosurgery, 2021, v. 135, n. 5, p. 1501, doi. 10.3171/2020.9.JNS202900
- By:
- Publication type:
- Article
A Parisian spring: the debate on language localization at the Imperial Academy of Medicine, Paris, April 4-June 13, 1865.
- Published in:
- Neurosurgical Focus, 2019, v. 47, n. 3, p. 1, doi. 10.3171/2019.6.FOCUS19256
- By:
- Publication type:
- Article
The Black Box of Board Process: gaining access to a difficult subject.
- Published in:
- Corporate Governance: An International Review, 2007, v. 15, n. 5, p. 843, doi. 10.1111/j.1467-8683.2007.00617.x
- By:
- Publication type:
- Article
Assessing Board Leadership.
- Published in:
- Corporate Governance: An International Review, 2005, v. 13, n. 5, p. 654, doi. 10.1111/j.1467-8683.2005.00457.x
- By:
- Publication type:
- Article
What's Wrong with Corporate Governance: a note.
- Published in:
- Corporate Governance: An International Review, 2004, v. 12, n. 4, p. 436, doi. 10.1111/j.1467-8683.2004.00385.x
- By:
- Publication type:
- Article
Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4687, doi. 10.3390/cancers15194687
- By:
- Publication type:
- Article
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 5, p. 815, doi. 10.1111/ejh.14082
- By:
- Publication type:
- Article
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 416, doi. 10.1111/ejh.13678
- By:
- Publication type:
- Article
The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 673, doi. 10.1111/ejh.13596
- By:
- Publication type:
- Article
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 17, p. 1, doi. 10.1002/cam4.70192
- By:
- Publication type:
- Article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
- By:
- Publication type:
- Article
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4357, doi. 10.1002/cam4.5245
- By:
- Publication type:
- Article
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.826342
- By:
- Publication type:
- Article
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus.
- Published in:
- Advances in Hematology, 2012, p. 1, doi. 10.1155/2012/621958
- By:
- Publication type:
- Article
s.Baer and s.Rickart Modules.
- Published in:
- Journal of Algebra & Its Applications, 2015, v. 14, n. 8, p. -1, doi. 10.1142/S0219498815501315
- By:
- Publication type:
- Article
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. e286, doi. 10.1016/j.clml.2023.06.001
- By:
- Publication type:
- Article
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 484, doi. 10.1016/j.clml.2023.03.006
- By:
- Publication type:
- Article
First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 340, doi. 10.1016/j.clml.2023.01.016
- By:
- Publication type:
- Article
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 608, doi. 10.1016/j.clml.2022.03.002
- By:
- Publication type:
- Article
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 1, p. e41, doi. 10.1016/j.clml.2021.07.028
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e259, doi. 10.1016/j.clml.2019.09.428
- By:
- Publication type:
- Article
The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e250, doi. 10.1016/j.clml.2019.09.414
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e55, doi. 10.1016/j.clml.2019.09.084
- By:
- Publication type:
- Article
Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e41, doi. 10.1016/j.clml.2019.09.063
- By:
- Publication type:
- Article
HR's Role in Corporate Governance.
- Published in:
- 2015
- By:
- Publication type:
- Interview
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Recommendations for Undergraduate Software Engineering Curricula.
- Published in:
- IEEE Software, 2006, v. 23, n. 6, p. 19, doi. 10.1109/MS.2006.171
- By:
- Publication type:
- Article
IMPROVING OUTCOME IN MULTIPLE MYELOMA.
- Published in:
- 2011
- By:
- Publication type:
- Proceeding
Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma.
- Published in:
- Journal of Neuro-Oncology, 2008, v. 90, n. 1, p. 63, doi. 10.1007/s11060-008-9632-3
- By:
- Publication type:
- Article
Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma.
- Published in:
- Oncologist, 2013, v. 18, n. 5, p. 611, doi. 10.1634/theoncologist.2012-0384
- By:
- Publication type:
- Article
Functional PET Scanning in the Preoperative Assessment of Cerebral Arteriovenous Malformations.
- Published in:
- Stereotactic & Functional Neurosurgery, 1995, v. 65, n. 1-4, p. 60, doi. 10.1159/000098898
- By:
- Publication type:
- Article
Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
- Published in:
- Clinical Transplantation, 2020, v. 34, n. 12, p. 1, doi. 10.1111/ctr.14099
- By:
- Publication type:
- Article